In accordance with these preclinical data, there is increasing clinical evidence that the combination of ICIs with antiangiogenic agents may not only be tolerable but also efficacious in prolonging survival as compared to ICI monotherapy in advanced NSCLC, while a variety of angiogenesis biomarkers, such as the VEGF family, are being studied for their potential utility as predictors of prognosis and treatment response in immunotherapy-treated NSCLC [24,25,26,27]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.